Niagen Bioscience (NAGE) said Monday its ChromaDex subsidiary has acquired from Queen's University Belfast the patent portfolio for nicotinamide riboside previously shared or licensed to ChromaDex.

Under an assignment agreement, the university assigned to ChromaDex all of its right, title and interest in the patent rights in exchange for an upfront payment of about $1 million, annual payments of $500,000 and 35,000 British pounds ($47,071) from 2026 through 2038, and one-time payments of $1.5 million and $2 million in 2035 and 2038 respectively, Niagen said in its filing with the US Securities and Exchange Commission.

Niagen said the acquired portfolio consists of the core patents supporting the production, composition and commercial use of nicotinamide riboside.

The assignment agreement, executed by ChromaDex and the university last week, terminated their 2015 licensing and joint ownership agreement, Niagen said.

Shares of Niagen were up more than 7% in recent Monday trading.

Price: 6.98, Change: +0.46, Percent Change: +7.06